1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,300 | 2,800 | 09:09 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | ABL Diagnostics: ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million | 2 | Euronext | ||
| 01.10. | ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million | 483 | Business Wire | Revised guidance includes the expected contribution from TEXCELL activities since their acquisition in the second half of 2026 Revised 2026 revenue guidance of €13.5 million to €14.0 million... ► Artikel lesen | |
| 30.09. | ABL Diagnostics: ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report | - | Euronext | ||
| 30.09. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report | 370 | Business Wire | Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting... ► Artikel lesen | |
| 21.09. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States | 798 | Business Wire | The Company signs a non-binding letter of intent to acquire 100% of Vela Operations Singapore and Vela Diagnostics USA, with the ambition to consolidate an integrated international platform covering... ► Artikel lesen | |
| ABL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 17.09. | ABL Diagnostics Becomes ABL Texcell Diagnostics | 573 | Business Wire | Shareholders confirm the continuation of the Company's listing on the regulated market of Euronext Paris as the most appropriate framework to support the Company's next phase of long-term development
Regulatory... ► Artikel lesen | |
| 17.09. | ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026 | 303 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris Compartment B ISIN: FR001400AHX6 ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences... ► Artikel lesen | |
| 15.09. | ABL Diagnostics to Participate in the European Main MidCap Event Paris 2026 on September 30 and October 1, 2026 | 437 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris Compartment B ISIN: FR001400AHX6 ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences... ► Artikel lesen | |
| 14.09. | ABL Diagnostics SA: ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report | 580 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services... ► Artikel lesen | |
| 11.09. | ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen | 557 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting... ► Artikel lesen | |
| 10.09. | ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics | 494 | Business Wire | Preparation of validation batches for the CER-001 bioproduction process based on viral safety studies A key step in the industrial and regulatory dossier toward a future market launch for... ► Artikel lesen | |
| 10.09. | ABL Diagnostics - TEXCELL Strengthens Its Position as an International Reference in Safety and Viral Clearance With a New Strategic Partnership With ABIONYX Pharma | 640 | Business Wire | • Selection of ABL Diagnostics' TEXCELL division for CER-001 viral safety and clearance studies • Support for a key stage of ABIONYX Pharma's industrial and regulatory program • Confirmation... ► Artikel lesen | |
| 08.09. | ABL Diagnostics Confirms Its Change of Scale in the First Half of 2026: Revenue up 90.0%, EBITDA Multiplied by More Than Four and Net Income up 343.3% Compared to the First Half of 2025 | 512 | Business Wire | In six months, ABL Diagnostics has already achieved 77.9% of 2025 annual sales and 29.7% higher than the net profit recorded for the full 2025 financial year Revenue of €5.415 million in H1... ► Artikel lesen | |
| 27.08. | ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Number of Shares Constituting the Share Capital | 392 | Business Wire | (Articles L. 233-8, II of the French Commercial Code and 223-16 of the AMF General Regulation)
Regulatory News:
ABL Diagnostics: (Paris:ABLD)
Date Total Number of Shares... ► Artikel lesen | |
| 27.08. | ABL Diagnostics: Ordinary and Extraordinary General Meeting of September 17, 2026 - Arrangements for the Availability and Consultation of Preparatory Documents | 424 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) informs its shareholders that they are invited to attend an Ordinary and Extraordinary General Meeting to be held on Thursday, September 17, 2026,... ► Artikel lesen | |
| 07.08. | ABL Diagnostics - Proposed Transfer of the Listing of Its Securities From the Regulated Market of Euronext Paris to Euronext Growth Paris | 874 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), an international company specializing in innovative molecular biology tests and global solutions for... ► Artikel lesen | |
| 29.07. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 477 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 27.07. | ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital | 510 | Business Wire | Introduction of a minimum floor price of €4.50 per share for any future drawdown
Reduction of the maximum drawdown size from 50,000 to 2,500 shares
Immediate return of 98,026 loaned... ► Artikel lesen | |
| 23.07. | ABL Diagnostics acquires TEXCELL assets for €2.9 million | 3 | Investing.com | ||
| 23.07. | ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL's Operations | 477 | Business Wire | Strengthening Life Sciences and Infectious Diseases Activities at Genopole, with Synergies in Virology, Biosafety, and Biological Control
Regulatory News:
ABL Diagnostics (Euronext Paris Compartment... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 38,560 | 0,00 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| THERMO FISHER | 586,40 | -0,81 % | Thermo Fisher Scientific: Strategische Neuausrichtung und Margenwachstum! | ||
| STRATEC | 22,800 | 0,00 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| UNIDOC HEALTH | 0,050 | -9,39 % | XFRA L7T: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| DIASORIN | 76,22 | -0,65 % | DiaSorin Reports Lower H1 Profit, Confirms FY26 Outlook | ROME (dpa-AFX) - DiaSorin S.p.A. (DIA.MI) on Friday, reported lower revenue and net profit for the first half of 2026, as higher operating expenses and weaker profitability offset growth recorded... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,420 | 0,00 % | Fresenius Medical Care Aktie: Wechsel an der Konzernspitze | Fresenius Medical Care bekommt kurzfristig einen neuen Vorstandschef. Shervin J. Korangy übernimmt mit Wirkung zum 12. Oktober 2026 den Vorsitz des Vorstands. Der Aufsichtsrat hat die Personalie am... ► Artikel lesen | |
| FRESENIUS | 43,285 | 0,00 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige Kontrolle über seine Biosimilars-Plattform | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Strategische Unternehmensentscheidung
Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige... ► Artikel lesen | |
| PROGYNY | 27,550 | 0,00 % | Progyny expects 1.2 million new covered lives in 2027 | ||
| BRIGHTSPRING HEALTH SERVICES | 63,84 | +0,06 % | BMO Capital reiterates Outperform on BrightSpring Health stock | ||
| HEARTFLOW | 49,335 | -0,05 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,540 | 0,00 % | Alignment Healthcare USA, LLC: Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027 | ||
| KESTRA MEDICAL TECHNOLOGIES | 26,490 | 0,00 % | Piper Sandler reiterates Kestra Medical stock rating on patent potential | ||
| CARL ZEISS MEDITEC | 31,820 | 0,00 % | 200-Tage-Linie hält: Goldman verpasst Zeiss Meditec einen Dämpfer | Goldman Sachs stuft Carl Zeiss Meditec auf "Sell" ab und senkt das Kursziel auf 23 Euro. Zwischenzeitlich verlor das Papier gut sieben Prozent, fing sich dann aber knapp über der 200-Tage-Linie. Die... ► Artikel lesen | |
| BILLIONTOONE | 95,70 | -0,05 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,310 | 0,00 % | Aveanna Healthcare Holdings, Inc. - 8-K, Current Report |
Das Unternehmen ABL DIAGNOSTICS SA kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,900 Euro und damit -2,06 % im Minus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,22 Euro errechnet sich eine Dividendendrendite von +11,58 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABL DIAGNOSTICS SA finden Sie auf Wallstreet Online.